Products with Antibacterial bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4724 | 3-O-trans-p-Coumaroyltormentic acid |
| 1. 3-O-(E)-p-coumaroyl tormentic acid induces apoptotic cell death in human leukemia (HL60) via mainly mitochondrial pathway by, at least in part, Topo I inhibition, it may be promising lead compound for developing an effective drug for treatment of leukemia. 2. 3-O-trans-p-coumaroyltormentic acid shows cytotoxicity against four human tumor cell lines (A549, SK-OV-3, SK-MEL-2, and HCT-15) in vitro, the IC50 values of 13.72, 14.29,14.61, 14.04 uM, respectively. 3. 3beta-O-cis-p-Coumaroyltormentic acid, and 3beta-O-trans-p-coumaroyltormentic acid are weakly selective for vancomycin-resistant Enterococcus (VRE) compared with eukaryotic cells, with an MIC of 59.4microg/mL and a 50% inhibitory concentration (IC50) of 72.0microg/mL for monkey kidney epithelial (MA104) cells. 4. A mixture of 3-O-cis-p-coumaroyltormentic acid and 3-O-trans-p-coumaroyltormentic acid shows an inhibitory effect comparable to (-)-epigallocatechin gallate (EGCG) of green tea on the activation of Epstein-Barr virus early antigen (EBV-EA) induced by 12-O-tetradeca--noylphorbol-13-acetate (TPA). | |
| BCN4741 | Stilbostemin N |
| 1. Stilbostemins N may exhibit moderate antibacterial activities. | |
| BCN4745 | Goniotriol |
| 1. Goniotriol exhibits antiplasmodial activity against Plasmodium falciparum (IC50=2.6 microg/mL). 2. Goniotriol shows antimycobacterial activity against Mycobacterium tuberculosis (MIC =100 microg/mL). 3. Goniotriol shows cytotoxicity against cancer cells, KB, BC1, NCI-H187, and MCF-7 with IC(50) ranging from 0.4 to 22.7 microg/mL. | |
| BCN4775 | 3',4'-Dihydroxyacetophenone |
| 1. 3',4'-Dihydroxyacetophenone has antimicrobial activity. | |
| BCN4786 | Altholactone |
| 1. Altholactone can inhibit the growth of various types of cancer cells through inducing apoptosis via oxidative stress, including bladder cancer, colon carcinoma cells. 2. Altholactone may be a potential antimicrobial agent, particularly in ciprofloxacin-refractory S. aureus and E. faecalis infections. | |
